IP Library Granted Patent US 7,858,633
Granted Patent B2
US 7,858,633 · App. 11/567,276 · Granted Dec 28, 2010

Cycloalkyl substituted pyrimidinediamine compounds and their uses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,858,633
App. No.
11/567,276
Granted
Dec 28, 2010
Kind
B2
Abstract

The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.

Claims (25)

1. A compound according to structural formula (I):

or a salt or N-oxide thereof, wherein:

R 2 is a (C6-C20)aryl, 5-20 membered heteroaryl, (C7-C28)arylalkyl or 6-28 membered heteroarylalkyl group, each optionally substituted with one or more of the same or different R 8 groups;

R 4 is a saturated or unsaturated, bridged (C3-C16)cycloalkyl ring substituted with an R 7 group;

R 5 is selected from hydrogen, (C1-C8)allyl optionally substituted with one or more of the same or different R 8 groups, and an electronegative group; and

R 7 is —C(O)OR d or —C(O)NR d R d ,

wherein

the electronegative group is selected from the group consisting of —CN, —NC, —NO 2 , halo, (C1-C3)haloalkyl, (C1-C3)perhaloalkyl, (C1-C3)fluoroalkyl, (C1-C3)perfluoroalkyl, —CF 3 , (C1-C3)haloalkoxy, (C1-C3)perhaloalkoxy, (C1-C3)fluoroalkoxy, (C1-C3)perfluoroalkoxy, —OCF 3 , —C(O)R a , —C(O)OR a , —C(O)CF 3 , and —C(O)OCF 3 ;

each R 8 group is, independently of the others, selected from a water-solubilizing group, R a , R b , (C3-C8)cycloalkyl optionally substituted with one or more of the same or different R a and/or R b groups, lower heterocycloalkyl optionally substituted with one or more of the same or different R a and/or R b groups, (C1-C8)alkoxy optionally substituted with one or more of the same or different R b groups and —O—(CH 2 ) x —R b , where x is an integer ranging from 1 to 6;

each R a is, independently of the others, selected from hydrogen, (C1-C8)alkyl, (C3-C8)cycloalkyl, (C6-C14)aryl, naphthyl, (C7-C20)arylalkyl and benzyl;

each R b is, independently of the others, selected from ═O, —OR a , (C1-C3) haloalkyloxy, —OCF 3 , ═S, —SR a , ═NR a , ═NOR a , —NR c R c , halogen, —CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , ═N 2 , —N 3 , —S(O)R a , —S(O) 2 R a , —S(O) 2 OR a , —S(O)NR a R a , —S(O) 2 NR c R c , —OS(O)R a , —OS(O) 2 R a , —OS(O) 2 OR a , —OS(O) 2 NR c R c , —C(O)R a , —C(O)OR a , —C(O)NR c R c , —C(NH)NR c R c , —C(NR a )NR c R c , —C(NOH)R a , —C(NOH)NR c R c , —OC(O)R a , —OC(O)OR a , —OC(O)NR c R c , —OC(NH)NR c R c and —OC(NR a )NR c R c ;

each R c is, independently of the others, selected from R a or, alternatively, two R c that are bonded to the same nitrogen atom may be taken together with this nitrogen atom to form a 5-8 membered heterocycloalkyl group which may optionally include from 1 to 3 additional heteroatomic groups selected from O, S, N—(CH 2 ) y —R a , N—(CH 2 ) y —C(O)R a , N—(CH 2 ) y —C(O)OR a , N—(CH 2 ) y —S(O) 2 R a , N—(CH 2 ) y —S(O) 2 OR a and N—(CH 2 ) y —C(O)NR a R a , where y is an integer ranging from 0 to 6, and which may optionally include one or more of the same or different R 8 and/or (C1-C8)alkyl substituents; and

each R d is, independently of the others, selected from R a , R c and a chiral auxiliary group; and

the water-solubilizing group is of the formula:

morpholino, piperidinyl, (C1-C6)N-alkyl piperidinyl, N-methyl piperidinyl, piperazinyl, (C1-C6)N-alkylpiperazinyl, N-methylpiperazinyl, N-ethyl piperidinyl, N-ethyl piperazinyl, pyrrolidinyl, N-alkyl pyrrolidinyl, N-methyl pyrrolidinyl, diazepinyl, N-ethyl pyrrolidinyl, N-alkyl azepinyl, N-methyl azepinyl, N-ethyl azepinyl, homopiperazinyl, N-methyl homopiperazinyl, N-ethyl homopiperazinyl, imidazoyl, where Y is selected from CH and N, Z is selected from CH 2 , O, S, N, NH, N—(CH 2 ) y —R a , N—(CH 2 ) y —C(O)R a , N—(CH 2 ) y —C(O)OR a , N—(CH 2 ) y —S(O) 2 R a , N—(CH 2 ) y —S(O) 2 OR a and N—(CH 2 ) y —C(O)NR c R c , with the proviso that Y and Z are not both simultaneously CH and CH 2 , respectively; and

the chiral auxiliary group is

wherein R 9 is hydrogen or (C1-C8) alkyl.

2. The compound according to claim 1 , wherein R 2 is a substituted phenyl of the formula:

wherein one of R 11 , R 12 or R 13 is a water-solubilizing group, and the other two of R 11 , R 12 and R 13 are each, independently of one another, selected from hydrogen, lower alkyl, (C1-C3) alkyl, methyl, halo, chloro, fluoro, hydroxy, (C1-C3) hydroxyalkyl, —O(CH 2 ) x —R b , —NR c R c , —C(O)NR c R c , —C(O)NHR a and —C(O)NHCH 3 .

3. The compound according to claim 2 wherein, R 11 is hydrogen;

R 12 is selected from

morpholino, piperidinyl, (C1-C3) N-alkyl piperidinyl, N-methyl piperidinyl, piperazinyl, (C1-C3) N-alkylpiperazinyl, N-methylpiperazinyl, N-ethyl piperidinyl, N-ethyl piperazinyl, pyrrolidinyl, N-alkyl pyrrolidinyl, N-methylpyrrolidinyl, diazepinyl, N-ethyl pyrrolidinyl, N-alkyl azepinyl, N-methyl azepinyl, N-ethyl azepinyl, homopiperazinyl, N-methyl homopiperazinyl, N-ethyl homopiperazinyl and imidazoyl; and

R 13 is selected from hydrogen, methyl, methoxy, trifluoromethyl and chloro.

4. A composition comprising a compound according to claim 1 and a carrier, excipient and/or diluent.

5. The composition of claim 4 in which the carrier, excipient and/or diluent is acceptable for pharmaceutical uses.

Assignments (3)
SECURITY INTEREST Recorded May 8, 2026
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 075576/0880 →
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2011
From: LI, HUI; ARGADE, ANKUSH; SINGH, RAJINDER; THOTA, SAMBAIAH; CARROLL, DAVID; TSO, KIN; TAYLOR, VANESSA; MCLAUGHLIN, JOHN; MARKOVTSOV, VADIM
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 025883/0784 →